花沐医疗 develops implant-grade absorbable/degradable biomaterials and a portfolio of regenerative-medicine implant products across spine, sports medicine, neurosurgery/craniofacial, aesthetics, and ophthalmology. The company has proprietary material technologies and a platform pipeline that includes an absorbable self-locking interbody fusion device, absorbable interface screws, absorbable suture-anchor (带线) anchors, and an absorbable craniofacial fixation system. Since its 2016 founding the company has attracted multiple institutional investors and holds several research-to-product translations and national research grants. The recent financing will be used to continue materials and product R&D, advance clinical trials, and accelerate product commercialization and market rollout. 花沐 has built a near-complete market operations team, completed national channel screening, prepared key hospitals and provinces, and expects multiple product registrations to boost commercialization in the near term. Huamu Medical has built an implant‑grade, absorbable materials technology platform and has developed multiple department-specific products including absorbable interbody fusion devices, composite ligament fixation nails, suture-anchor nails, and craniofacial fixation systems. Its first sports‑medicine absorbable product entered clinical stages in 2020. The company says its product lineup covers spine, trauma repair, sports medicine, maxillofacial and neurosurgery indications and aims to replace traditional implants with degradable biomaterials. Huamu completed a nearly RMB 100 million B round, and plans to use the proceeds to carry out multicenter clinical trials for its in‑house products and to advance registration and commercialization of degradable biomaterials. Management and investors view the degradable implant segment in China as largely vacant and long dominated by foreign firms such as Johnson & Johnson, Medtronic and Stryker, giving Huamu potential to break import dependence given its technical accumulation and product breadth.

Total raised

$14M

Funding rounds

2

Latest round

Series B

Latest activity

Feb 2020